Noa Therapeutics
Developer of a proprietary nuclear factor erythroid 2-related factor 2 (Nrf2)-biased platform designed to target the aryl hydrocarbon receptor, a key regulator of innate immunity and barrier homeostas...
Valuation
$0
Share Price
N/A
Total Raised
$1.7M
Last Round
N/A